To help, Wounded Warrior Project (WWP) is working with Cohen Veterans Bioscience (CVB) to identify and study biomarkers that could improve treatment options. A biomarker is a measurable substance indicative of a disease or infection. For veterans, a specific biomarker found in a blood sample can confirm a PTSD diagnosis and the potential to respond to treatment.
By studying these substances, researchers hope to better target PTSD treatment in veterans and other trauma survivors.
“We would love to cure PTSD and TBI one day,” said Mike Richardson, WWP vice president of mental health and independence services. “Until then, we will continue to target treatment and do what is best for the veterans we serve.”
As part of this support Wounded Warrior Project’s Warrior Care Network will be actively involved in the research into biomarkers testing wounded veterans and helping identify the most effective treatment options. Warrior Care Network is an innovative partnership with four top facilities focused on providing world-class mental health care to wounded veterans. While the treatment shows clinically proven results, more can still be done.
“We value Wounded Warrior Project’s collaboration and support to help advance a first generation of PTSD & TBI diagnostics,” said Magali Haas, MD, PhD, CVB’s CEO & President. “We need an all-hands approach to tackle this important scientific & clinical challenge.”
This collaboration can advance a roadmap for discovery, replication, and qualification of biomarkers an effort that can create solutions in years, not decades.
SOURCE: Wounded Warrior Project
